Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancrelipase for BMI in Metastatic PDAC
NCT05642962Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2022
- Primary completion
- Nov 2026
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pancrelipase in pancreatic ductal adenocarcinoma (PDAC), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2022; status: active, not recruiting.
02
Drugs
pancrelipase
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05642962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642962.